Objective: The prognosis of ovarian cancer has improved because of platinum-and taxanecontaining chemotherapy. We investigated the 5-year disease-specific overall survival and prognostic factors of patients with advanced ovarian cancer to elucidate the change in clinical course of ovarian cancer with the advance of chemotherapy for patients who developed relapse in the era before the addition of molecular targeting therapy. Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGO Stage III and IV) treated in the past 11 years (1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010). We classified the patients into two groups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) and those who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year diseasespecific overall survival and median survival rates between these two groups. We also investigated the prognostic factors of 104 patients who developed relapse. Results: The 5-year disease-specific overall survival rate was significantly higher in Group B than A (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride, non-clear cell adenocarcinoma and intestinal resection were independent prognostic factors. Conclusions: The induction of new chemotherapeutic drugs and the increased variation of secondor third-line chemotherapy affected the improvement in overall survival of patients with advanced epithelial ovarian cancer.
Introduction
Ovarian cancer is the 11th most common cancer in Japanese women. In 2010, the National Cancer Center estimated that 9918 new cases are diagnosed per year. In 2013, 4713 deaths due to ovarian cancer occurred in Japan. About 40-50% of patients with ovarian cancer are diagnosed at the advanced stage (Stage III/IV) (1) . Maximal cytoreduction and platinum-based chemotherapy are used in the treatment of advanced ovarian cancer. With respect to chemotherapy for ovarian cancer, alkylating agent-containing chemotherapy changed to paclitaxel (PTX)/platinum chemotherapy after publication of a report by McGuire et al. in 1996 (2) . Pegylated liposomal doxorubicin hydrochloride (PLD) and gemcitabine hydrochloride (GEM) have recently been used to advanced ovarian cancer that has relapsed after the completion of platinum-and taxane-based chemotherapy (3) (4) (5) . Additionally, the Gynecologic Cancer InterGroup International Collaboration on Ovarian Neoplasms (ICON7) trial and the complementary Gynecologic Oncology Group study 0218 reported improved progression-free survival after treatment of ovarian cancer by bevacizumab (6, 7) . In Japan, the addition of bevacizumab to standard chemotherapy in the first-line treatment of ovarian cancer began to be used for some patients in 2013. However, there is no report on whether the prognosis of advanced ovarian cancer improved before the era of molecular targeting therapy in Japan. It is important to evaluate the prognosis of ovarian cancer before the use of molecular targeting drugs. Evaluation of changes in the prognosis of epithelial ovarian cancer secondary to induction of PLD and GEM is meaningful.
The first purpose of this study was to confirm the improvement in the prognosis of advanced ovarian cancer in the past half-decade. The second purpose was to prove that this improvement is attributable to the use of new chemotherapeutic drugs for patients with recurrent ovarian cancer. Approval was obtained from Institutional Review Board review.
Methods
During a recent 11-year time span (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) , 267 patients with newly diagnosed epithelial ovarian cancer were treated in our hospital. We reviewed the precise clinical course of 134 (50.2%) patients with advanced epithelial ovarian cancer (Stage III, n = 98; Stage IV, n = 36). Maximal cytoreduction and adjuvant chemotherapy with paclitaxel/carboplatin (PTX/CBDCA) was used for all patients. After first-line therapy, all patients without detection of a residual lesion underwent regular screening for recurrence of ovarian cancer every 3-6 months. At each visit, serum tumor marker measurements and pelvic examinations were conducted. Complete blood counts and biochemical tests were conducted as required.
The following protocol is used in our institution. PTX/CBDCA chemotherapy was used as first-line chemotherapy for patients with advanced ovarian cancer beginning in 1999. When cancer recurrence was detected in patients with platinum-sensitive, chemotherapy with platinum and taxane was used again. If patients with ovarian cancer had been diagnosed with platinum-resistant cancer, then cisplatin/irinotecan (CDDP/CPT-11), cisplatin/gemcitabine hydrochloride (CDDP/GEM), CBDCA/PLD or monotherapy was used as second-line chemotherapy. After third-line chemotherapy, patients with platinumsensitive ovarian cancer received platinum-containing chemotherapy, and those with platinum-resistant ovarian cancer received monotherapy without platinum.
Since 2009, PLD or GEM has been used as second-or third-line chemotherapy in our institution. Nogitecan is also as third-or fourthline chemotherapy for some patients. After second-line chemotherapy, the anticancer drugs are selected on a case-by-case basis. Basically, we select new drugs to minimize each patient's symptoms according to the profile of adverse effects.
In the present study, we classified the 134 patients (50.2%) with advanced ovarian cancer (FIGO Stage III and IV) into two groups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) and those who had been diagnosed from 2006 to 2010 (Group B). As mentioned above, PLD or GEM has been used as the second-/third-line chemotherapy in our institution since 2009. Long-term survivors in Group A had also undergone chemotherapy by PLD and/or GEM from 2009 for their second and subsequent relapses.
Statistical analysis
All patients in this study have received regular screening for recurrence of gynecologic malignancies during 5-16 years (Group A: 10-16 years, Group B: 5-9 years). Patient demographics and survey responses were summarized using descriptive statistics. We compared long-term survival not limited to 5-year disease-specific overall survival between the two groups. We evaluated using the follow-up interval to 5 years and compared the 5-year disease-specific overall survival between the two groups by log-rank test. We also investigated the prognostic factors in the 104 patients with relapsed Stage III/IV ovarian cancer. Multivariable analysis was performed with the Cox proportional hazards model to evaluate independent factors affecting survival. A P value of <0.05 was considered statistically significant. Analyses were carried out with SAS for Windows, release 9.4 (SAS Institute, Cary, NC). Of the 134 patients, 104 (77.6%) had relapsed and the 29 patients (21.6%) had not relapsed. The prognosis of the remaining one patient was unclear due to hospital transfer. In Group A, the 5-year disease-related overall survival rate was 38.6% and the median survival time was 44.3 ± 5.1 months. In Group B, the 5-year diseaserelated overall survival rate was 67.0% and the median survival time was 67.7 ± 5.1 months (P = 0.0311) (Fig. 1) . The patients' clinical characteristics are shown in Table 1 . In Groups A and B, 29.6% and 48.1% of patients, respectively, had undergone more than three regimens (P < 0.05). There were no differences in the other factors between the two groups ( Table 1) .
Prognostic factors in patients with relapse of FIGO Stage III/IV ovarian cancer
We also investigated the prognostic factors among the 104 patients with relapsed ovarian cancer (FIGO Stage III and IV) after 1999 to determine the changes in the clinical course of ovarian cancer with the advance of chemotherapy for treatment of relapse. The results of the multivariate analysis of the prognostic factor for improved survival in patients with relapsed Stage III/IV ovarian cancer are shown in Table 2 . Multivariate analysis showed that the FIGO stage (Stage IV vs. III: hazard ratio (HR), 1.912; 95% confidence interval (95% CI), 1.153-3.169; P = 0.0120), histological findings (non-clear cell adenocarcinoma vs. clear cell adenocarcinoma: HR, 0.274; 95% CI, 0.131-0.574; P = 0.0006), use of PLD (HR, 0.430; 95% CI, 0.238-0.776; P = 0.0051), and intestinal resection (HR, 1.920; 95% CI, 1.022-3.606; P = 0.0424) were independent prognostic factors.
Discussion
In the present study, we confirmed improvement in the prognosis of advanced ovarian cancer from 1999 to 2010. Patients with recurrent ovarian cancer now have improved survival due to more effective anticancer drugs (8, 9) . In our institution, about half of the patients with recurrence of advanced ovarian cancer have received chemotherapy beyond third-line treatment for recurrence since 2006 ( Table 1) . As a matter of course, we need to consider the platinumfree interval of each patient; multiple regimens of chemotherapy for recurrent ovarian cancer are of value (8) .
Chemotherapy with PTX/CBDCA has been used as first-line chemotherapy for all patients with advanced ovarian cancer since 1999 in our institution. In the chemotherapy for recurrent ovarian cancer patients, CDDP/CPT-11 or monotherapy with taxane had been used for second or third-line chemotherapy until 2005. From 2006, GEM and PLD came to be used for second or third-line chemotherapy. We divided from 1999 to 2005 and from 2006 to 2010 according to changes of second or third-line chemotherapy and compared the 5-year disease-related overall survival rate and median survival time between these two groups to reveal the prognosis of epithelial ovarian cancer within 5 years.
As we mentioned before, the anticancer drugs are selected on a case-by-case basis after second-line chemotherapy. In patients with platinum-sensitive, platinum-containing chemotherapy was used again. If patients had been diagnosed with platinum-resistant cancer, we selected new drugs to minimize each patient's symptoms taking quality of life and profile of adverse effects into the consideration. It is very complicated to demonstrate progression-free survival of primary therapy, recurrent therapy or second line, third line independently because there were no rule in the rank order of the anticancer drugs. In this situation, we believe the overall survival is the most simple and reliable endpoint to demonstrate the difference of the two era of chemotherapy, and choose only the overall survival as an endpoint.
We also investigated the prognostic factors for relapsed ovarian cancer (FIGO Stage III and IV) after 1999 to identify the reason for the improved prognosis. We found that the 5-year disease-related overall survival rate of patients with advanced ovarian cancer was significantly higher in Group B than A (67.0% vs. 38.6%, respectively; P = 0.0311) (Fig. 1) . The independent prognostic factors in this study were the FIGO stage, histological type (non-clear cell adenocarcinoma), use of PLD, and intestinal resection during the debulking surgery. The prognosis in patients who had undergone intestinal resection was poor (HR, 1.920; 95% CI, 1.022-3.606; P = 0.0424). The factors that we analyzed in the univariate and multivariable analysis in the patients with relapsed Stage III/IV ovarian cancer were FIGO stage, histology (clear cell carcinoma vs. clear . We could compare long-term survival not limited to 5-year disease-specific overall survival between the two groups. However, confounding factors may have affected the long-term survivors. For example, some of the long-term survivors might be treated with new anticancer drugs as third-or fourthline chemotherapy. Thus, we limited the follow-up interval to 5 years and compared the 5-year disease-specific overall survival between the two groups by log rank test instead of comparing disease-specific overall survival. cell carcinoma), indication of PLD and/or GEM, age, presence of residual disease, presence of dissemination to the diaphragm, number of regimen (more than 3 regimens or not) and intestinal resection. Since the multivariate analysis is used to adjust for covariate effects, even if a factor is not significant in univariate analysis, it becomes significant in multivariate analysis.
Various factors that could have caused the improvement in the prognosis should be considered, including surgery for advanced ovarian cancer, adjuvant chemotherapy and the sensitivity of the diagnosis of recurrence. Each is discussed below.
With respect to surgery for advanced ovarian cancer, there was no change in the surgical methods in our institution during the study period. Several studies have shown that optimal cytoreductive surgery is an important factor impacting survival (10) (11) (12) . Tumor debulking with hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic lymphadenectomy para-aortic lymph node biopsy and appendectomy are standard operations in our institution. When ovarian cancer has infiltrated the intestinal tract, intestinal resection is performed for complete excision of the cancer. In the present study, however, multivariate analysis showed that patients who had undergone intestinal resection had a poor prognosis (HR, 1.920; 95% CI, 1.022-3.606; P = 0.0424). The extent of the cancer at diagnosis is one of the most important factors impacting survival. Additionally, there were no differences in the residual disease or incidence of intestinal resection between the two groups ( Table 1) . Based on the above findings, the surgical methods did not seem to contribute to the improvement in the prognosis of ovarian cancer in this study. And the biological behavior of ovarian cancer by itself that tends to infiltrate the intestinal tract might be an important prognostic factor.
In terms of adjuvant chemotherapy, molecular targeted drugs were not used until 2013. Chemotherapy with PTX/CBDCA has been used as first-line chemotherapy for patients with advanced ovarian cancer since 1999. Intraperitoneal chemotherapy has not been used in our institution. Thus, adjuvant chemotherapy also did not contribute to the improvement in the prognosis of advanced ovarian cancer.
Finally, with respect to the sensitivity of the diagnosis of recurrence, all patients underwent regular screening for recurrence of gynecologic malignancies every 3-6 months. At each visit, serum tumor marker measurement, routine vaginal cytology and pelvic examination were conducted. Furthermore, complete blood counts and biochemical tests were conducted as required. In addition, regular computed tomography scans were performed to follow up advanced ovarian cancer in both eras. For these reasons, we do not believe that the diagnostic sensitivity of these regular screening tests for recurrence influenced the improvement in the 5-year diseaserelated survival of advanced ovarian cancer in Group B.
Platinum sensitivity is the most important factor affecting the prognosis of advanced/recurrent ovarian cancer (3). Histologically, clear cell carcinoma of the ovary is platinum-or chemotherapyresistant (13) . It is reasonable that clear cell carcinoma was identified as an independent prognostic factor. However, the incidence of this histological type was not different between Groups A and B. The histology of ovarian cancer also did not affect the improvement in the prognosis.
Consequently, the improvement in the median overall survival time of patients with advanced ovarian cancer during the last 5 years might have been owing to the diversity in the second-and third-line chemotherapy for ovarian cancer. The Cox proportional hazards model indicated that chemotherapy with PLD was significantly associated with better overall survival in the multivariate analysis. A previous study demonstrated that PLD is not inferior to PTX/CBDCA in terms of progression-free survival and is superior in patients with platinum-sensitive recurrent ovarian cancer when used with CBDCA (4). The increased variation in second-or third-line chemotherapy might have affected the improvement in the overall survival of patients with advanced ovarian cancer because the patients in Group B had undergone more regimens than those in Group A (Table 1) .
In the present study, we clarified the improvement of the prognosis of ovarian cancer in the recent years before induction of molecular targeting agents, and estimate that the reason of the improvement is probably owing to the usage of new chemotherapeutic agents in the treatment of recurrent ovarian cancer.
However, the study has several limitations. First, this was a retrospective study that compared the prognosis of two groups of patients with advanced ovarian cancer treated in different years. We need to consider some points when comparing the prognosis of patients diagnosed and treated in different years. One is the change in prognosis due to the change in systemic therapy. Another is the difference in the sensitivity of the diagnosis of recurrence. Still another is the difference in the number of recurrence due to the different follow-up intervals. However, there were no changes in the systemic therapy for advanced ovarian cancer except chemotherapy with PLD or GEM in our institution. Additionally, all patients underwent regular screening for recurrence of gynecologic malignancies every 3-6 months. This protocol has not changed for the past 20 years. Furthermore, we compared the 5-year disease-related overall survival rates between the two groups using the same follow-up interval.
The second limitation is that confounding factors may have affected the long-term survivors. For example, some of the long- term survivors in Group A had been treated with PLD and/or GEM as third-or fourth-line chemotherapy. Thus, we limited the followup interval to 5 years and compared the 5-year disease-related overall survival between the two groups. In recent years, bevacizumab has also been used in combination with PTX plus CBDCA as part of the initial therapy for patients with ovarian cancer. In one study, the use of bevacizumab during and up to 10 months after PTX and CBDCA chemotherapy prolonged the median progression-free survival time by~4 months in patients with advanced epithelial ovarian cancer, but the overall survival remained unchanged (6, 7) . However, the treatment for relapsed ovarian cancer had some severe side effects in that study. For example, severe bone marrow suppression, peripheral nerve disorders, and secondary leukemia developed in the long-term survivors with advanced ovarian cancer after aggressive use of various types of anticancer drugs. Hypertension, venous thromboembolism and gastrointestinal events were reported in association with the use of bevacizumab (6) .
Before utilizing new molecular targeting agents, we should know that the prognosis of advanced ovarian cancer has already been improved by the use of new chemotherapeutic drugs in patients with recurrent ovarian cancer. Awareness of this change in the prognosis of ovarian cancer is especially important considering the complications associated with use of these new agents. Treatment selection for relapsed ovarian cancer must be based on a patient's request with a goal of prolonging life and QOL. In period subject to this study, supportive care had also developed gradually. For example, early palliative care for recurrent patients with gynecological cancer had started from 2012 in our institution. Supportive care also important factor that influence the prognosis of the cancer patients (14) . We need to continue the investigation of the factors that influence the prognosis of ovarian cancer patients.
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